University of Michigan Rogel Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Michigan Rogel Cancer Center sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
University of Michigan Rogel Cancer Center: 292 sponsored US clinical trials, 45 recruiting.
University of Michigan Rogel Cancer Center sponsors 292 registered US clinical trials on ClinicalTrials.gov, 45 of them currently recruiting, and 167 completed. 4 of these trials are in Phase 3-4 (later-stage) and 182 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
University of Michigan Rogel Cancer Center ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 229 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 3 of 6
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
NCT04076579
Acupressure for Fatigue in Ovarian Cancer Survivors
NCT03763838
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
NCT03829722
Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface
NCT04530526
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
NCT03300505
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
NCT03785873
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
NCT03601819
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
NCT03927105
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
NCT03562507
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
NCT03639935
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
NCT03559049
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
NCT03570619
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
NCT03556904
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
NCT03689582
The ConnectedCancerCare Pilot Study (CCC)
NCT03618017
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
NCT03287063
Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy
NCT03515356
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
NCT03416153
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
NCT03228186
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
NCT03240016
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
NCT03287050
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
NCT03286114
The SMART CART Study: Health Information Technology
NCT04051216
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
NCT03352427
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
NCT03208712
Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT03194373
Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
NCT03242915
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
NCT03101566
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT03135171
The Validation of a Novel Adherence Method for Oral Oncolytics
NCT03561272
Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
NCT02946008
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
NCT02989714
Functional Imaging in Lung SBRT
NCT03121300
Genomics in Michigan Impacting Observation or Radiation
NCT02783950
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
NCT02784288
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
NCT02805179
Expansion Trial for Axitinib In Head And Neck Cancer
NCT02762513
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
NCT02729194
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
NCT02613598
Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer
NCT02712437
Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell Transplant
NCT02734797
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
NCT02400463
Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
NCT02485470
A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
NCT02460835
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT02492867
Patient and Caregiver Participation Through an Educational Health Information Technology System ("BMT Roadmap") in the Context of Hematopoietic Cell Transplantation
NCT03161665
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
NCT02463994
Early Imaging Biomarkers in NSCLC
NCT03121287
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
NCT02409121
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
NCT02436408
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 126 |
| Phase 3 | 2 |
| Phase 4 | 2 |
What is open in the University of Michigan Rogel Cancer Center pipeline
45 recruiting of 292 indexed (15% open); 167 completed (57%).
Phase mix: 4 late (III/IV) vs 182 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Michigan Rogel Cancer Center: open-pipeline peers nationwide
Peers matched on 292 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Michigan Rogel Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
Related
What to do with this University of Michigan Rogel Cancer Center page
292 registered trials is a research-attention snapshot, not an endorsement of University of Michigan Rogel Cancer Center or any single study.
- 45 of University of Michigan Rogel Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of Michigan Rogel Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Michigan Rogel Cancer Center pipeline card: 292 registered trials from official public datasets.Report a data error.